Anavex Life Sciences Corp (AVXL)

[Steady_T]

Maybe 3-71 could be helpful in Covid. That is an issue that is sometime in the future.

Anavex's immediate concern is getting the MOA (method of action) of 2-73 confirmed in a controlled trial and following that up with an NDA approval. The company needs a revenue stream more than anything else at this point in it developmental cycle.

An approved MDA confirms the MOA and that will legitimize 2-73 in the eyes of investors and the wider medical community. That will also improve the perception of 3-71 as a potential successful drug candidate.

Covid indication for Anavex is high risk indication with a huge amount of research for potential competitors going on. Anavex has all the risk it can handle at the moment. A failure of any Anavex drug in a Covid trial at this point in time would be a very big setback for the company and how it is perceived in the marketplace. Going for a Covid trial right now would be perceived as desperation on the company's part.